Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 9/20 | 0.57 |
| ▸ | TGM2 | P21980 | 9/20 | 0.54 |
| ▸ | F13A1 | P00488 | 6/20 | 0.54 |
| ▸ | TGM1 | P22735 | 3/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5633204 | 0.93 | TGM2 (0.53) | F10TGM2F13A1TGM1 | |
| SCHEMBL5632520 | 0.89 | TGM2 (0.52) | F10TGM2F13A1TGM1 | |
| SCHEMBL6790392 | 0.88 | PKM (0.65) | TGM2F13A1TGM1PKM | |
| SCHEMBL710366 | 0.88 | TGM2 (0.64) | TGM2F13A1TGM1PKM | |
| SCHEMBL5202414 | 0.86 | STS (0.57) | F10TGM2F13A1TGM1 | |
| SCHEMBL2378015 | 0.86 | TGM2 (0.54) | TGM2F13A1TGM1 | |
| SCHEMBL6977155 | 0.84 | TGM2 (0.62) | TGM2F13A1TGM1PKM | |
| SCHEMBL14490210 | 0.83 | TGM2 (0.59) | TGM2F13A1TGM1PKM | |
| SCHEMBL567503 | 0.83 | ATM (0.54) | F10TGM2F13A1TGM1PKM | |
| SCHEMBL2376710 | 0.82 | ABL1 (0.59) | TGM2F13A1TGM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0986551-B1 | SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL (JP) | 2006-08-02 | — | — | EP | disclosed |
| US-20040082786-A1 | Piperazine based inhibitors of factor xa | MILENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| EP-1322610-A2 | PIPERAZINE BASED INHIBITORS OF FACTOR Xa | Millennium Pharmaceuticals, Inc. (US) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002026720-A2 | PIPERAZINE BASED INHIBITORS OF FACTOR Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-04-04 | — | — | WO | disclosed |
| US-6359134-B1 | ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-03-19 | — | — | US | disclosed |
| EP-0986551-A1 | SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Pharmaceutical Company Limited (JP) | 2000-03-22 | — | — | EP | disclosed |
| WO-1998054164-A1 | SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082786-A1 | Piperazine based inhibitors of factor xa | TFPI, F11, F12 | F10 11/4885TGM2 2873/4885F13A1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.